TY  - GEN
AU  - Vanrenterghem,Yves
AU  - Bresnahan,Barbara
AU  - Campistol,Josep
AU  - Durrbach,Antoine
AU  - Grinyó,Josep
AU  - Neumayer,Hans-Hellmut
AU  - Lang,Philippe
AU  - Larsen,Christian P
AU  - Mancilla-Urrea,Eduardo
AU  - Pestana,José Medina
AU  - Block,Alan
AU  - Duan,Tao
AU  - Glicklich,Alan
AU  - Gujrathi,Sheila
AU  - Vincenti,Flavio
TI  - Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)
SN  - 1534-6080
PY  - 2011///0701
KW  - Abatacept
KW  - Adult
KW  - Aged
KW  - Blood Glucose
KW  - metabolism
KW  - Blood Pressure
KW  - drug effects
KW  - Cardiovascular Diseases
KW  - etiology
KW  - Cyclosporine
KW  - adverse effects
KW  - Diabetes Mellitus
KW  - blood
KW  - Female
KW  - Humans
KW  - Immunoconjugates
KW  - Immunosuppressive Agents
KW  - Kidney Transplantation
KW  - Lipids
KW  - Male
KW  - Middle Aged
KW  - Risk Factors
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/TP.0b013e31820c10eb
ER  -